Kura Oncology Inc. shares (NASDAQ:KURA) shot 72.3 percent higher to $11.80 Friday on news that its lead candidate, tipifarnib, hit the primary endpoint of a phase II trial in HRAS-mutant relapsed or refractory squamous cell carcinomas of the head and neck (SCCHN) before the trial had even completed enrolling. Four confirmed partial responses and two patients with stable disease were observed among the first six evaluable patients enrolled, and two patients showed objective responses beyond one year. Kura said it will continue to enroll additional patients.